Posted by Michael Wonder on 27 Mar 2023
Enhertu approved in Japan as the first HER2 directed therapy for patients with HER2 low metastatic breast cancer
27 March 2023 - Approval based on DESTINY-Breast04 results showing Enhertu reduced the risk of disease progression or death by 50% versus chemotherapy.
Daiichi Sankyo today announced that Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with HER2 low (IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy.
